FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to an amorphous solid dispersion comprising a tetrazole derivative of the formula (II) or (III) or a pharmaceutically acceptable salt thereof as an active ingredient and a water-soluble polymer, wherein the water-soluble polymer is hypromellose, which is included in an amount of 0.1 to 4 parts by weight, based on 1 part by weight of the active ingredient. Invention also relates to pharmaceutical P-glycoprotein inhibitors comprising an amorphous solid dispersion..
EFFECT: technical result: an amorphous solid dispersion comprises a tetrazole derivative of formula (II) or (III) having improved solubility and absorption rate, and thus can be effectively used to reduce multi-drug resistance (MDR) in cancer cells.
10 cl, 5 dwg, 8 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID DISPERSIONS OF INSOLUBLE DRUGS AND METHODS OF THEIR PREPARATION | 2013 |
|
RU2646491C2 |
| DRUG COMPOSITIONS CONTAINING CONTROLLED RELEASE HYPROMELLOSE MATRIXES | 2006 |
|
RU2414241C2 |
| AMORPHOUS SOLID DISPERSION COMPRISING TAXANE, TABLET COMPRISING SAME, AND METHOD FOR PREPARING SAME | 2015 |
|
RU2684632C2 |
| SOLID DISPERSIONS CONTAINING APOPTOSIS PROMOTING PROTEINS | 2010 |
|
RU2550134C2 |
| REVAPRAZAN-CONTAINING SOLID DISPERSION AND METHOD FOR PREPARING IT | 2007 |
|
RU2461382C2 |
| TMC 125 PREPARATION SPRAY DRYING PRODUCTION PROCESS | 2007 |
|
RU2406502C2 |
| PHARMACEUTICAL COMPOSITIONS | 1996 |
|
RU2159107C2 |
| PHARMACEUTICAL COMPOSITION OF PYRAZOLE COMPOUND DISPERSED IN POLYMER MATRIX | 2020 |
|
RU2826604C1 |
| PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2809144C2 |
| SOLID DISPERSIONS, CONTAINING KINASE INHIBITORS | 2011 |
|
RU2566716C2 |
